Yataro Yoshida
Kyoto University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yataro Yoshida.
Leukemia Research | 1996
Masayo Ido; Chisato Nagata; Norito Kawakami; Hiroyuki Shimizu; Yataro Yoshida; Takeo Nomura; Hideaki Mizoguchi
To determine the risk factors of the myelodysplastic syndromes (MDS) we conducted a case-control study in Japan. One hundred and sixteen MDS patients were diagnosed from 1 September to 31 October 1992 and from 1 August to 31 October 1993 in the 32 hospitals enrolled in the idiopathic Disorders of Hematopoietic Organs Research Committee. Age, sex, and hospital-matched controls were selected for each case. Information on cigarette smoking and drinking habits, hair dye use, history of keeping pet animals, and occupational exposures to organic solvents, lead and radiation was obtained from self-administered questionnaires. Conditional logistic regression was applied to this individually matched case-control study and odds ratios (ORs) were computed to estimate association between each exposure variable and risk of MDS. Alcohol drinking was associated with increased risk of MDS (OR = 2.15; 95% confidence interval = 1.12-4.16) and there was a significant trend in risk with increasing amounts of ethanol consumed per week (P < 0.05). We also found elevated ORs for cigarette smokers (OR = 1.80), users of hair dye products (OR = 1.77), and workers exposed to organic solvents (OR = 1.50), although these ratios were not statistically significant. Exposure to pet animals was not associated with risk of MDS. The association observed between alcohol drinking and MDS was still eminent even after adjusted with other variables of cigarette smoking, hair dye use and occupational exposure to organic solvents, and the dose-response relationship was also confirmed.
Leukemia Research | 1997
Naoyuki Anzai; Hiroshi Kawabata; Terutoshi Hishita; Yataro Yoshida; Yasunori Ueda; Minoru Okuma
Endonucleases capable of producing internucleosomal DNA cleavage are one of the key enzymes in apoptosis. We examined endonuclease activities contained in nuclei of CD34+ and erythroid cells in the bone marrow (BM) from 12 patients with the myelodysplastic syndromes. The levels of Mg(2+)-dependent and acidic endonucleases showed little changes as compared with those from normal BM. By contrast, the level of Ca2+/Mg(2+)-dependent endonuclease was appreciably higher in MDS erythroid cells than normal counterparts, although the activity varied markedly in CD34+ and erythroid cells. Our results suggested that Ca2+/Mg(2+)-dependent endonuclease is related to ineffective erythropoiesis in MDS.
Leukemia Research | 1997
Shigeru Oguma; Yataro Yoshida; Minoru Okuma; Haruto Uchino; Tadashi Maekawa; Takeo Nomura; Hideaki Mizoguchi
Chronological changes in hematological findings were analyzed in 225 patients with myelodysplastic syndromes (MDS). They were diagnosed between 1990 and 1992. Their hematological findings, i.e. hemoglobin levels, leukocyte and platelet counts, proportions of peripheral blood (PB) blasts and monocytes, and proportion of blasts in bone marrow (BM), were recorded for up to 42 months after diagnosis, when available. BM was examined regularly in only a few patients. Therefore, it was impractical to use the French-American-British Cooperative Group criteria for subtype classification during the disease course. Thus, we used the percentage of PB blasts as the only indicator of stage evolution. We classified the disease into four stages: stage 1, less than 1% PB blasts; stage 2, 1-5% PB blasts; stage 3, 5-30% PB blasts; and stage 4, 30% or more PB blasts. There were 171 patients initially in stage 1, 37 initially in stage 2, and 17 initially in stage 3. Less than half (45%) of the patients initially in stage 1 progressed to stage 2, while 91% of the patients initially in stage 2 and all of the patients initially in stage 3 showed stage evolution. Eight variables, i.e. BM blasts 5% or more, male sex, karyotypic abnormalities, micromegakaryocytes, mononuclear large megakaryocytes, platelet counts 50 x 10(9)/l or higher, abnormal nucleus of granulocytes, and abnormal granules of granulocytes, were found to be significant risk factors for evolution from stage 1 to 2. Evolution from stage 1 to a higher stage within 15 months of diagnosis was associated with impending poor prognosis in most patients. However, of the 67 patients initially in stage 1 who died, 30 did not show stage evolution. Evolution from stage 2 to a higher stage and from stage 3 to stage 4 was also associated with impending poor prognosis. Higher levels of cytopenia were not associated with poorer prognosis in the stage 1 patients. In conclusion, our grading system proved to be useful in evaluating the chronological changes in MDS patients.
American Journal of Hematology | 1997
Shuichi Shiga; Toshihito Furukawa; Itsuko Koyanagi; Morihisa Yamagishi; Yataro Yoshida; Takayuki Takahashi; Reiji Kannagi; Toru Mori
To establish a simple computer program for the laboratory diagnosis of anemia and related diseases, multivariate analyses were applied to the results of routine hematological laboratory tests obtained from 48 patients and 51 healthy volunteers. The patients studied were limited to those who had not been treated hematologically by the time of their first visit to our hospital, and their first data obtained in our laboratory were analyzed. Final diagnoses were aplastic anemia (AA) in 21, myelodysplastic syndrome (MDS) in 14, iron deficiency anemia (IDA) in 3, polycytemia vera (PV)in 3, and idiopathic thrombocytopenic purpura (ITP) in 7. Eight parameters, WBC, RBC, Hb, Ht, MCV, MCH, MCHC, and PLT, were transformed to normal distribution and then applied to principal component analysis to evaluate their independence. Very close relationships were observed between Ht and Hb, and between MCV and MCH. One each of these pairs was selected by discriminant analysis and two sets, RBC, MCH, Hb, PLT, and WBC, and RBC, MCV, Ht, PLT, and WBC, were obtained. Two canonical components gave good discrimination of these five diseases and also of normal subjects. When disease prediction was made using this analysis, 37 of 48 patients (77.1%) were predicted correctly, and furthermore, when two disease predictions were allowed, all patients were diagnosed properly. Some overlaps were observed in this two‐dimensional coordinate system, especially of AA and MDS, and also with normal subjects. To improve the system further, the additional parameters of age and sex were added to construct a three‐dimensional analysis which resulted in much clearer discrimination. The whole procedure described is being developed with subjects who are not taking medication. Subsequently, the general application of this analytical procedure should be limited to only those not on medications. In conclusion, this is in essence a demonstration project; however, this trial of laboratory diagnosis using routine hematological laboratory results appears to be promising. Further extension of the study by increasing numbers of patients and disorders studied, including secondary anemias, will allow the design of diagnostic software for use with personal computers at the sites of primary care. Am. J. Hematol. 54:108–117, 1997
Critical Reviews in Oncology Hematology | 1996
Yataro Yoshida; Naoyuki Anzai; Hiroshi Kawabata
Pathologie Biologie | 1997
Yataro Yoshida; Hiroshi Kawabata; Naoyuki Anzai; Kaoru Tohyama
Leukemia | 1996
Hiroshi Kawabata; Naoyuki Anzai; Yasunori Ueda; Hiroshi Masutani; Hirama T; Yataro Yoshida; Minoru Okuma
Seminars in Hematology | 1996
Yataro Yoshida
Oncologist | 1997
Kaoru Tohyama; Hiroshi Tsutani; Yuji Wano; Hiromichi Iwasaki; Toshihiro Fukushima; Yoshimasa Urasaki; Yasukazu Kawai; Toru Nakamura; Yataro Yoshida; Takanori Ueda
Leukemia Research | 1997
Yataro Yoshida